SignatureFD
CAPR icon

SignatureFD’s Capricor Therapeutics CAPR Stock Holding History

SignatureFD’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$10.4K Buy
1,094
+993
+983% +$11K ﹤0.01% 2710
2026
Q2 		$2.43K Buy
+101
New +$3.06K ﹤0.01% 3097
2025
Q2 		– Sell
-82
Closed -$778 – 3287
2025
Q1 		$778 Buy
+82
New +$1.14K ﹤0.01% 3097
2024
Q4 		– Sell
-393
Closed -$5.98K – 3324
2024
Q3 		$5.98K Hold
393
– – ﹤0.01% 2518
2024
Q2 		$1.88K Buy
+393
New +$2.19K ﹤0.01% 2770

Other funds holding CAPR

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
HBK Sorce Advisory
HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

SignatureFD's CAPR Position: Q3 2026 in Review

SignatureFD increased its Capricor Therapeutics (CAPR) stake by 983% in Q3 2026, buying an estimated $11K and bringing the position to 1,094 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2710.

SignatureFD first reported a position in CAPR in Q2 2024 and has held it in 5 quarters since. 62 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • SignatureFD held 1,094 shares of Capricor Therapeutics worth $10.4K as of Q3 2026.
  • SignatureFD bought 993 Capricor Therapeutics shares in Q3 2026, an estimated $11K.
  • Capricor Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2710 holding.
  • SignatureFD first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 62 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.